227 related articles for article (PubMed ID: 34721027)
1. Dynamics of Adaptive Immune Cell and NK Cell Subsets in Patients With Ankylosing Spondylitis After IL-17A Inhibition by Secukinumab.
Jiang Y; Yang M; Zhang Y; Huang Y; Wu J; Xie Y; Wei Q; Liao Z; Gu J
Front Pharmacol; 2021; 12():738316. PubMed ID: 34721027
[No Abstract] [Full Text] [Related]
2. TNF-α inhibitor therapy can improve the immune imbalance of CD4+ T cells and negative regulatory cells but not CD8+ T cells in ankylosing spondylitis.
Yang M; Lv Q; Wei Q; Jiang Y; Qi J; Xiao M; Fang L; Xie Y; Cao S; Lin Z; Zhang Y; Tu L; Zhao M; Pan Y; Jin O; Gu J
Arthritis Res Ther; 2020 Jun; 22(1):149. PubMed ID: 32560733
[TBL] [Abstract][Full Text] [Related]
3. Decreased frequencies of circulating follicular helper T cell counterparts and plasmablasts in ankylosing spondylitis patients Naïve for TNF blockers.
Bautista-Caro MB; Arroyo-Villa I; Castillo-Gallego C; de Miguel E; Peiteado D; Plasencia-Rodríguez C; Villalba A; Sánchez-Mateos P; Puig-Kröger A; Martín-Mola E; Miranda-Carús ME
PLoS One; 2014; 9(9):e107086. PubMed ID: 25203742
[TBL] [Abstract][Full Text] [Related]
4. Increased IL-22- and IL-17A-Producing Mucosal-Associated Invariant T Cells in the Peripheral Blood of Patients With Ankylosing Spondylitis.
Toussirot É; Laheurte C; Gaugler B; Gabriel D; Saas P
Front Immunol; 2018; 9():1610. PubMed ID: 30057583
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Anti-TNF Therapy on CD4+ and CD8+ Cell Subsets in Ankylosing Spondylitis.
Dulic S; Vasarhelyi Z; Bajnok A; Szalay B; Toldi G; Kovacs L; Balog A
Pathobiology; 2018; 85(3):201-210. PubMed ID: 29212085
[TBL] [Abstract][Full Text] [Related]
6. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond.
Dubash S; Bridgewood C; McGonagle D; Marzo-Ortega H
Expert Rev Clin Immunol; 2019 Feb; 15(2):123-134. PubMed ID: 30576610
[TBL] [Abstract][Full Text] [Related]
7. Imbalance of Peripheral Lymphocyte Subsets in Patients With Ankylosing Spondylitis: A Meta-Analysis.
Liu D; Liu B; Lin C; Gu J
Front Immunol; 2021; 12():696973. PubMed ID: 34295337
[TBL] [Abstract][Full Text] [Related]
8. Higher frequency of peripheral blood interleukin 21 positive follicular helper T cells in patients with ankylosing spondylitis.
Xiao F; Zhang HY; Liu YJ; Zhao D; Shan YX; Jiang YF
J Rheumatol; 2013 Dec; 40(12):2029-37. PubMed ID: 24187103
[TBL] [Abstract][Full Text] [Related]
9. High frequency of circulating follicular helper T cells is correlated with B cell subtypes in patients with ankylosing spondylitis.
Long S; Ma L; Wang D; Shang X
Exp Ther Med; 2018 May; 15(5):4578-4586. PubMed ID: 29731839
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab (AIN457) in the treatment of ankylosing spondylitis.
Braun J; Baraliakos X; Kiltz U
Expert Opin Biol Ther; 2016; 16(5):711-22. PubMed ID: 26982813
[TBL] [Abstract][Full Text] [Related]
11. Effect of IL-17A blockade with secukinumab in autoimmune diseases.
Patel DD; Lee DM; Kolbinger F; Antoni C
Ann Rheum Dis; 2013 Apr; 72 Suppl 2():ii116-23. PubMed ID: 23253932
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated Peripheral Invariant Natural Killer T Cells in Plaque Psoriasis Patients.
Hu Y; Chen Y; Chen Z; Zhang X; Guo C; Yu Z; Xu P; Sun L; Zhou X; Gong Y; Yu Q; Shi Y
Front Cell Dev Biol; 2021; 9():799560. PubMed ID: 35186952
[No Abstract] [Full Text] [Related]
13. IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis.
Krueger JG; Wharton KA; Schlitt T; Suprun M; Torene RI; Jiang X; Wang CQ; Fuentes-Duculan J; Hartmann N; Peters T; Koroleva I; Hillenbrand R; Letzkus M; Yu X; Li Y; Glueck A; Hasselberg A; Flannery B; Suárez-Fariñas M; Hueber W
J Allergy Clin Immunol; 2019 Sep; 144(3):750-763. PubMed ID: 31129129
[TBL] [Abstract][Full Text] [Related]
14. Safety of secukinumab for the treatment of active ankylosing spondylitis.
Loricera J; Galíndez-Aguirregoikoa E; Blanco R
Expert Opin Drug Saf; 2021 Jun; 20(6):627-634. PubMed ID: 33470130
[No Abstract] [Full Text] [Related]
15. [Clinical features of imbalance between Th1 and Th22 cells and its association with disease progression in patients with liver cirrhosis].
Wu HQ; Zhao JJ; Li HW; Zhang Z
Zhonghua Gan Zang Bing Za Zhi; 2017 Oct; 25(10):738-744. PubMed ID: 29108201
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM
J Med Econ; 2019 Jan; 22(1):45-52. PubMed ID: 30346844
[TBL] [Abstract][Full Text] [Related]
17. Immune Monitoring of Patients With Primary Immune Regulation Disorders Unravels Higher Frequencies of Follicular T Cells With Different Profiles That Associate With Alterations in B Cell Subsets.
Caldirola MS; Martínez MP; Bezrodnik L; Zwirner NW; Gaillard MI
Front Immunol; 2020; 11():576724. PubMed ID: 33193371
[TBL] [Abstract][Full Text] [Related]
18. Altered circulating T follicular helper cell subsets in patients with psoriasis vulgaris.
Wang Y; Wang L; Shi Y; Wang F; Yang H; Han S; Bai Y
Immunol Lett; 2017 Jan; 181():101-108. PubMed ID: 27662792
[TBL] [Abstract][Full Text] [Related]
19. Immunophenotyping in pemphigus reveals a T
Holstein J; Solimani F; Baum C; Meier K; Pollmann R; Didona D; Tekath T; Dugas M; Casadei N; Hudemann C; Polakova A; Matthes J; Schäfer I; Yazdi AS; Eming R; Hertl M; Pfützner W; Ghoreschi K; Möbs C
J Allergy Clin Immunol; 2021 Jun; 147(6):2358-2369. PubMed ID: 33221382
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
Katsevman GA; Mariscal G; Barrios C; Domenech-Fernández P; Ziembinski C; Bhatia S
Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):160-166. PubMed ID: 33001775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
